ArticleOncoimmunology2020

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.

Lorena Incorvaia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.